We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Pfizer, Goldman Sachs, General Electric, Microchip Technology and Genuine Parts
Read MoreHide Full Article
For Immediate Release
Chicago, IL – November 16, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer Inc. (PFE - Free Report) , The Goldman Sachs Group, Inc. (GS - Free Report) , General Electric Co. (GE - Free Report) , Microchip Technology Inc. (MCHP - Free Report) and Genuine Parts Co. (GPC - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Pfizer, Goldman Sachs and General Electric
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE - Free Report) , The Goldman Sachs Group, Inc. (GS - Free Report) and General Electric Co. (GE - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Pfizer have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-0.7% vs. +10.3%). The company is facing currency flactuation and pricing pressure which are key top-line headwinds. Concerns remain about its long-term growth drivers beyond its COVID-related products due to competitive pressure.
However, there is no company as strongly placed in the COVID vaccines/treatment market as Pfizer right now. Its COVID-19 vaccine together with the oral antiviral pill for COVID-19, Paxlovid is expected to generate a combined $54 billion in sales in 2022. Pfizer boasts a sustainable pipeline with multiple late-stage programs that can drive growth.
Nevertheless, according to the Zacks analyst estimate Pfizer’s top line suggest a CAGR decline of around 30% over the next three years. Estimates are stable ahead of Q3 earnings. Pfizer has a decent record of earnings surprises in the recent quarters.
Goldman Sachs’ shares have declined -5.2% over the past year against the Zacks Financial - Investment Bank industry’s decline of -10.7%. The company’s a decline in equities revenues is likely to hurt the Global Market segment. A rise in the expense base will hinder the bottom line. Also, legal hassles and higher dependence on overseas revenues are woes.
However, Goldman Sachs has a decent earnings surprise history. Its earnings outpaced the Zacks Consensus Estimate in three of the trailing four quarters and missed in the other one. The company continues to expand organically and bolster its digital consumer banking platform.
Other than business diversification, robust client engagement, a solid position in announced and completed mergers and acquisitions (M&As), and a decent investment banking (IB) backlog are likely to aid in navigating weaker markets. Also, its robust liquidity position will help sustain capital deployments.
General Electric’ shares have declined -17.0% over the past year against the Zacks Diversified Operations industry’s decline of -18.2%. The company supply chain disruptions, including labor and material shortages and high logistics costs are weighing on the company’s performance. Weakness in the Power and Renewable energy segment due to lower volumes is concerning.
Foreign currency headwinds are hurting the company’s top line. The company’s strong performance of the Aerospace and Healthcare segments is driving General Electric’s growth. Its investments in productivity and innovation should fuel growth going forward.
Cost-control measures and pricing actions are aiding its bottom line. The company’s measures to reward its shareholders are encouraging. In the first nine months of 2022, General Electric paid dividends of $455 million to shareholders and repurchased shares worth $0.6 billion.
Other noteworthy reports we are featuring today include Microchip Technology Inc. (MCHP - Free Report) and Genuine Parts Co. (GPC - Free Report) .
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Pfizer, Goldman Sachs, General Electric, Microchip Technology and Genuine Parts
For Immediate Release
Chicago, IL – November 16, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer Inc. (PFE - Free Report) , The Goldman Sachs Group, Inc. (GS - Free Report) , General Electric Co. (GE - Free Report) , Microchip Technology Inc. (MCHP - Free Report) and Genuine Parts Co. (GPC - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Pfizer, Goldman Sachs and General Electric
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE - Free Report) , The Goldman Sachs Group, Inc. (GS - Free Report) and General Electric Co. (GE - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Pfizer have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-0.7% vs. +10.3%). The company is facing currency flactuation and pricing pressure which are key top-line headwinds. Concerns remain about its long-term growth drivers beyond its COVID-related products due to competitive pressure.
However, there is no company as strongly placed in the COVID vaccines/treatment market as Pfizer right now. Its COVID-19 vaccine together with the oral antiviral pill for COVID-19, Paxlovid is expected to generate a combined $54 billion in sales in 2022. Pfizer boasts a sustainable pipeline with multiple late-stage programs that can drive growth.
Nevertheless, according to the Zacks analyst estimate Pfizer’s top line suggest a CAGR decline of around 30% over the next three years. Estimates are stable ahead of Q3 earnings. Pfizer has a decent record of earnings surprises in the recent quarters.
(You can read the full research report on Pfizer here >>>)
Goldman Sachs’ shares have declined -5.2% over the past year against the Zacks Financial - Investment Bank industry’s decline of -10.7%. The company’s a decline in equities revenues is likely to hurt the Global Market segment. A rise in the expense base will hinder the bottom line. Also, legal hassles and higher dependence on overseas revenues are woes.
However, Goldman Sachs has a decent earnings surprise history. Its earnings outpaced the Zacks Consensus Estimate in three of the trailing four quarters and missed in the other one. The company continues to expand organically and bolster its digital consumer banking platform.
Other than business diversification, robust client engagement, a solid position in announced and completed mergers and acquisitions (M&As), and a decent investment banking (IB) backlog are likely to aid in navigating weaker markets. Also, its robust liquidity position will help sustain capital deployments.
(You can read the full research report on Goldman Sachs here >>>)
General Electric’ shares have declined -17.0% over the past year against the Zacks Diversified Operations industry’s decline of -18.2%. The company supply chain disruptions, including labor and material shortages and high logistics costs are weighing on the company’s performance. Weakness in the Power and Renewable energy segment due to lower volumes is concerning.
Foreign currency headwinds are hurting the company’s top line. The company’s strong performance of the Aerospace and Healthcare segments is driving General Electric’s growth. Its investments in productivity and innovation should fuel growth going forward.
Cost-control measures and pricing actions are aiding its bottom line. The company’s measures to reward its shareholders are encouraging. In the first nine months of 2022, General Electric paid dividends of $455 million to shareholders and repurchased shares worth $0.6 billion.
(You can read the full research report on General Electric here >>>)
Other noteworthy reports we are featuring today include Microchip Technology Inc. (MCHP - Free Report) and Genuine Parts Co. (GPC - Free Report) .
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.